Boundless Bio Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Boundless Bio Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for BBI-825 in Solid Tumor (Phase 1).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Why Boundless Bio? | n/a | n/a | n/a | Public pipeline row |
| BBI-825 | Solid Tumor | n/a | Phase 1 | Public pipeline row |
| BBI-355 | n/a | n/a | Phase 1 | Public pipeline row |
| BBI-940 | Breast Cancer | Metastatic Breast Cancer | Advanced Breast Cancer | Small Molecule | Phase 1 | Public pipeline row |
Estimated cash runway: Runway > 12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT06299761 | Phase 1 | TERMINATED | 19 | 2025-06-25 |
| NCT05827614 | Phase 1 | ACTIVE_NOT_RECRUITING | 85 | 2026-09-30 |
| NCT07408089 | Phase 1 | RECRUITING | 96 | 2029-02-28 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.